Free press releases distribution network?

More news: Health/Surgery
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Increasing Awareness and Availability of Improved Products Boost European Urinary Incontinence Therapeutics Market - New analysis from Frost & Sullivan, European Urinary Incontinence Therapeutics Market, finds that the market was valued at $393.6 million in 2006 and estimates this to reach $967.0 million in 2013
Increasing Awareness and Availability of Improved Products Boost European Urinary Incontinence Therapeutics Market

 

PRZOOM - /newswire/ - London, United Kingdom, 2007/07/24 - New analysis from Frost & Sullivan, European Urinary Incontinence Therapeutics Market, finds that the market was valued at $393.6 million in 2006 and estimates this to reach $967.0 million in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The social stigma attached to urinary incontinence coupled with the side effects of some existing treatments are restraining market expansion. However, the recent launch of new and improved products, coupled with the anticipated launch of more novel offerings will help market participants to grow despite the challenges that exist in the market. Increasing awareness levels and priority given to urinary incontinence by both patients and medical professionals, will be key to widening the patient pool and boosting uptake levels.

New analysis from Frost & Sullivan (pharma.frost.com) European Urinary Incontinence Therapeutics Market, finds that the market was valued at $393.6 million in 2006 and estimates this to reach $967.0 million in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Urinary Incontinence Therapeutics Market, send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore[.]frost.com with your full name, company name, title, telephone number, email address, city, state and country. We will send you the information through email upon receipt of the above information.

“The urinary incontinence therapeutics market in Europe will experience sustained growth in the coming years,” notes Frost & Sullivan Research Analyst Vaibhav Sarvesh, “Rising awareness allied with the expected launch of improved products will be the major drivers in market expansion.”

Current therapeutic options are primarily geared to treat urge urinary incontinence and have been associated with side effects that nullify are effecting the performance of the drugs. However, recently launched products have a better safety profile and have been well accepted. More products with novel approaches are set to be introduced in the market and boost revenue prospects.

However, the low importance given to the disease by physicians coupled with the limited awareness of this condition will pose significant challenges to market growth. Moreover, the SUI therapeutics market faces stiff competition from alternative treatment options, thereby restraining potential market development.

“Well-established drugs will face very stiff competition from more recently released therapeutics and will show continuous decline in their market share,” adds Mr. Sarvesh. “The expected launch of some novel therapies will further reduce the market share of the older drug therapies, but will benefit the market in general as it will induce more patients to embrace therapeutic treatment for their condition.”

Increasing importance given to urinary incontinence by physicians will be key in augmenting the number of patients adopting therapeutics options. Novel treatments, expected to be launched for the treatment of urinary incontinence, will also positively impact market growth.

“The lack of therapeutic options for SUI will present the most obvious lacunae in this market,” concludes Mr. Sarvesh. “Raising awareness levels about the sole therapeutic option available for SUI will be critical for its success.”

European Urinary Incontinence Therapeutics Market is part of the Pharmaceutical & Biotechnology Subscription, which also includes research in the following markets: European Endometriosis Therapeutics Market, European Blockbusters coming off patent - Opportunities for Generics, and European Osteoarthritis Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Increasing Awareness and Availability of Improved Products Boost European Urinary Incontinence Therapeutics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Radhika Menon Theodore 
rmtheodore[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Ultimate Medical Group Announces A New Regenerative Medicine Division

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today